Incyte Corporation (INCY)
Incyte Corporation Revenues: 36.18M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
INCY Revenues Rankings
| Overall | 30th percentile | 3074 of 4425 |
| Sector | 54th percentile | 212 of 470 in Healthcare |
| Industry | 77th percentile | 30 of 132 in Biotechnology |
INCY Revenues Range, Past 5 Years
| Minimum | 0.614M | Jun 2008 |
| Maximum | 85.87M | Dec 2010 |
| Average | 17.04M |
About Revenues
Income that a company gains from business activities, calculated before any expenses are subtracted. Includes all sales and other increases in owner's equity.
Learn More
You may also be interested in these INCY related companies
INCY News
RT @billgunderson $INCY is another biotech that looks good. Number 31 overall.
about 2 days ago by howardlindzon
about 2 days ago by howardlindzon
Incyte's CEO Bank of America Merrill Lynch 2012 Health Care Conference (Transcript)
May 15, 9:02PM Seeking Alpha
May 15, 9:02PM Seeking Alpha
watching $INCY on a B/O over $24 to new highs ($28 is possible), few upgrades here recently also
about 17 days ago by HighGrowthFinancial
about 17 days ago by HighGrowthFinancial
RT @StockTiger $INCY http://stks.co/3ms7 from watch list volume is already 27% of full day average and over line < looks great
about 18 days ago by 1nvestor
about 18 days ago by 1nvestor
$INCY http://stks.co/3ms2 from watch list volume is already 27% of full day average and over line
about 18 days ago by StockTiger
about 18 days ago by StockTiger
Market Wrap Video + Additions to Watch List http://stks.co/3mmp including: $CVS, $INCY, $LNCE, $MRH, $PENN, $SYA, $WDC
about 18 days ago by StockTiger
about 18 days ago by StockTiger
Goldman Sachs Upgrades Incyte (INCY) to Buy, Positive on Jakafi and Pipeline; Sees as Possible M&A Target
May 11, 7:13AM Street Insider
May 11, 7:13AM Street Insider
♫ Market Wrap Video + Additions to Watch List http://stks.co/3mRQ including: $CVS, $INCY, $LNCE, $MRH, $PENN, $SYA, $WDC
about 19 days ago by StockTiger
about 19 days ago by StockTiger
$INCY is looking like it wants to go higher. My second highest rated biotech right now.
about 19 days ago by billgunderson
about 19 days ago by billgunderson
@reelimages $CHD & $INCY longs for today at the moment. did a U-turn in $CAT which I sold at 96.
about 19 days ago by 1nvestor
about 19 days ago by 1nvestor
Incyte to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
May 01, 4:10PM Business Wire
May 01, 4:10PM Business Wire
Incyte's Management Present at Barclays Capital 2012 Global Healthcare Conference (Transcript)
Mar 20, 3:48AM Seeking Alpha
Mar 20, 3:48AM Seeking Alpha
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| INCY | 22.38 | -0.03 | -0.13% | 2.853B |
| INAP | 7.17 | +0.04 | +0.56% | 375.96M |
| IN | 5.99 | +0.44 | +7.93% | 332.06M |
| IMT | 14.97 | +0.01 | +0.07% | |
| IMS | 14.55 | -0.03 | -0.21% | |
| IMRS | 3.17 | +0.05 | +1.60% | 142.68M |
| IMOS | 13.17 | +0.58 | +4.61% | 338.92M |
| IMO | 41.35 | +0.91 | +2.25% | 34.28B |
| IMN | 5.71 | +0.16 | +2.88% | 212.73M |
| IDSA | 5.13 | -0.02 | -0.39% | 35.74M |
